BIOMAT Database Logo BIOMAT Database Logo

Cytokine monitoring of infection and rejection in renal transplant recipients. 1995

V Daniel, and S Pasker, and M Wiesel, and S Carl, and S Pomer, and G Staehler, and R Schnobel, and R Weimer, and G Opelz
Department of Transplantation Immunology, University of Heidelberg, Germany.

UI MeSH Term Description Entries
D007378 Interleukins Soluble factors which stimulate growth-related activities of leukocytes as well as other cell types. They enhance cell proliferation and differentiation, DNA synthesis, secretion of other biologically active molecules and responses to immune and inflammatory stimuli. Interleukin
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D003141 Communicable Diseases An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host. Infectious Diseases,Communicable Disease,Disease, Communicable,Disease, Infectious,Diseases, Communicable,Diseases, Infectious,Infectious Disease
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D015166 Monitoring, Immunologic Testing of immune status in the diagnosis and therapy of cancer, immunoproliferative and immunodeficiency disorders, and autoimmune abnormalities. Changes in immune parameters are of special significance before, during and following organ transplantation. Strategies include measurement of tumor antigen and other markers (often by RADIOIMMUNOASSAY), studies of cellular or humoral immunity in cancer etiology, IMMUNOTHERAPY trials, etc. Immune Monitoring,Immunologic Monitoring,Immunosurveillance,Monitoring, Immune,Monitoring, Radioimmunologic,Monitoring, Immunological,Monitoring, Radioimmunological,Radioimmunologic Monitoring,Immunological Monitoring,Radioimmunological Monitoring
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D016030 Kidney Transplantation The transference of a kidney from one human or animal to another. Grafting, Kidney,Renal Transplantation,Transplantation, Kidney,Transplantation, Renal,Kidney Grafting,Kidney Transplantations,Renal Transplantations,Transplantations, Kidney,Transplantations, Renal

Related Publications

V Daniel, and S Pasker, and M Wiesel, and S Carl, and S Pomer, and G Staehler, and R Schnobel, and R Weimer, and G Opelz
Long-term CMV monitoring and chronic rejection in renal transplant recipients.
January 2023, Frontiers in cellular and infection microbiology,
V Daniel, and S Pasker, and M Wiesel, and S Carl, and S Pomer, and G Staehler, and R Schnobel, and R Weimer, and G Opelz
Value of pretransplantation cytokine profiles for predicting acute rejection in renal transplant recipients.
September 2005, Transplantation proceedings,
V Daniel, and S Pasker, and M Wiesel, and S Carl, and S Pomer, and G Staehler, and R Schnobel, and R Weimer, and G Opelz
Dysregulated cytokine responses during cytomegalovirus infection in renal transplant recipients.
July 2008, Transplantation,
V Daniel, and S Pasker, and M Wiesel, and S Carl, and S Pomer, and G Staehler, and R Schnobel, and R Weimer, and G Opelz
Monitoring tolerance and rejection in organ transplant recipients.
July 2011, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals,
V Daniel, and S Pasker, and M Wiesel, and S Carl, and S Pomer, and G Staehler, and R Schnobel, and R Weimer, and G Opelz
BKV QPCR detection and infection monitoring in renal transplant recipients.
July 2007, The new microbiologica,
V Daniel, and S Pasker, and M Wiesel, and S Carl, and S Pomer, and G Staehler, and R Schnobel, and R Weimer, and G Opelz
Acute rejection episodes in pediatric renal transplant recipients with cytomegalovirus infection.
June 2008, Pediatric transplantation,
V Daniel, and S Pasker, and M Wiesel, and S Carl, and S Pomer, and G Staehler, and R Schnobel, and R Weimer, and G Opelz
Late cellular rejection in renal transplant recipients.
February 1986, Transplantation,
V Daniel, and S Pasker, and M Wiesel, and S Carl, and S Pomer, and G Staehler, and R Schnobel, and R Weimer, and G Opelz
Pre-transplant Th1 and post-transplant Th2 cytokine patterns are associated with early acute rejection in renal transplant recipients.
April 2003, Clinical transplantation,
V Daniel, and S Pasker, and M Wiesel, and S Carl, and S Pomer, and G Staehler, and R Schnobel, and R Weimer, and G Opelz
Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection.
October 2001, Clinical transplantation,
V Daniel, and S Pasker, and M Wiesel, and S Carl, and S Pomer, and G Staehler, and R Schnobel, and R Weimer, and G Opelz
Predictors of chronic rejection in renal transplant recipients.
February 1993, Transplantation proceedings,
Copied contents to your clipboard!